<DOC>
	<DOCNO>NCT00332202</DOCNO>
	<brief_summary>This clinical research study investigate prevention relapse patient diffuse large B cell lymphoma ( DLBCL ) use enzastaurin daily . This randomised trial compare Enzastaurin Placebo ( dummy treatment ) , chance receive Enzastaurin 2 1 .</brief_summary>
	<brief_title>PRELUDE : Study Investigate Prevention Relapse Lymphoma Using Daily Enzastaurin</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Clinical diagnosis diffuse large B cell lymphoma Recently complete RCHOP therapy achieve remission IPI score 3,4,5 At least 18 year age Agree study followup schedule Have receive therapy RCHOP lymphoma Serious medical condition infection , second cancer , heart disease Received radiation one lesion Unable swallow tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>